Business Context and Reporting Period
Company: Aziyo Biologics, Inc. (Note: Request metadata listed "Elutia Inc.", but filing text confirms Aziyo Biologics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: May 27, 2022
Reporting Period: Event date May 27, 2022; Financial reference to Q1 2022 (ended March 31, 2022)
Listing Status: Class A Common Stock (Symbol: AZYO) on The Nasdaq Global Market
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. The only financial metric disclosed is:
- Stockholders' Equity: Reported in the Form 10-Q for the period ended March 31, 2022, as being below the $10.0 million threshold required for continued listing on the Nasdaq Global Market.
Material Changes
Delisting Notice: On May 27, 2022, the Company received a written notice from Nasdaq stating it failed to satisfy the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) due to insufficient stockholders' equity.
Outlook, Management Commentary, and Risks
- Immediate Effect: The notice has no immediate effect; the stock continues to trade on the Nasdaq Global Market.
- Compliance Plan: The Company has 45 days from the notice date to submit a plan to regain compliance with Nasdaq Global Market requirements.
- Strategic Intent: The Company currently intends to apply to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market tier, subject to satisfying that tier's listing requirements.
- Risk: Failure to regain compliance or successfully transfer tiers could result in delisting.
Investor Verification Checklist
- Verify the exact stockholders' equity figure reported in the Form 10-Q for the quarter ended March 31, 2022.
- Confirm the Company's submission of a compliance plan or transfer application within the 45-day window.
- Monitor the status of the transfer application to the Nasdaq Capital Market.
- Review subsequent filings for any updates on the Company's financial position or listing status.